RT Journal Article
SR Electronic
T1 The breast cancer research scandal: addressing the issues
JF Canadian Medical Association Journal
JO CMAJ
FD Canadian Medical Association
SP 1195
OP 1197
VO 152
IS 8
A1 C. Weijer
YR 1995
UL http://www.cmaj.ca/content/152/8/1195.abstract
AB The three claims put forward by Dr. Roger Poisson to rationalize his enrollment of ineligible subjects in clinical trials do not justify research fraud. None the less, certain lessons for the conduct of clinical research can be learned from the affair: experimental therapies should be made available to technically ineligible subjects when no effective therapy exists for their disease; further research must investigate the possible benefits of clinical-trial participation; broadly based, pragmatic trials must be regarded as the ideal model; and each eligibility criterion in a clinical-trial protocol should be justified.